Grove Bank & Trust Cuts Position in GSK plc (NYSE:GSK)

Grove Bank & Trust lowered its position in GSK plc (NYSE:GSK) by 7.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,621 shares of the pharmaceutical company’s stock after selling 455 shares during the quarter. Grove Bank & Trust’s holdings in GSK were worth $190,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. J2 Capital Management Inc purchased a new stake in shares of GSK during the 4th quarter worth $596,000. HF Advisory Group LLC lifted its holdings in GSK by 12.8% during the 4th quarter. HF Advisory Group LLC now owns 8,743 shares of the pharmaceutical company’s stock worth $296,000 after buying an additional 990 shares during the last quarter. Ameritas Advisory Services LLC lifted its holdings in GSK by 19.4% during the 4th quarter. Ameritas Advisory Services LLC now owns 34,955 shares of the pharmaceutical company’s stock worth $1,182,000 after buying an additional 5,668 shares during the last quarter. HB Wealth Management LLC acquired a new position in shares of GSK during the 4th quarter worth about $316,000. Finally, Premier Path Wealth Partners LLC increased its holdings in shares of GSK by 21.1% in the 4th quarter. Premier Path Wealth Partners LLC now owns 34,274 shares of the pharmaceutical company’s stock valued at $1,159,000 after acquiring an additional 5,967 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Up 0.0 %

GSK stock opened at $33.46 on Monday. The company has a market cap of $69.34 billion, a price-to-earnings ratio of 21.72, a price-to-earnings-growth ratio of 1.44 and a beta of 0.63. The company has a fifty day moving average price of $34.02 and a 200 day moving average price of $37.98. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.70%. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, November 15th. GSK’s dividend payout ratio is presently 96.10%.

Analysts Set New Price Targets

GSK has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 13th. Finally, Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and decreased their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.